Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
Kai M Beeh,1 Dave Singh,2 Lilla Di Scala,3 Anton Drollmann31insaf Respiratory Research Institute, Wiesbaden, Germany; 2University Of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UK; 3Novartis Pharma AG, Basel, SwitzerlandIntroduction: Exercise limitatio...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-07-01
|
| Series: | International Journal of COPD |
| Online Access: | http://www.dovepress.com/once-daily-nva237-improves-exercise-tolerance-from-the-first-dose-in-p-a10558 |